Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease – Eli Lilly and Company

Written by

admin

in

  1. Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease  Eli Lilly and Company
  2. EU Commission authorises medicine for treatment of Alzheimer’s disease early stages  Eunews
  3. Eli Lilly says EC grants marketing authorization for Kisunla  TipRanks
  4. EU approves contentious Alzheimer’s medication  Times of Malta

Continue Reading

More posts